FB102 is designed to block CD122 to selectively modulate IL-2 and IL-15 pathways that cause inflammation while preserving regulatory T-cell function and immune balance.

From the articleargenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease